Full title: Genetically informed drug target prioritisation and repurposing for major depressive disorder

Abigail R. ter Kuile[1], Chris Finan[2,3,4], Sandesh Chopade[2], Marion Van Vugt[2,4,5], Nikita Hukerikar[6], Serena Barral[7], Argyris Stringaris[1,8], Amand F. Schmidt[2,3,5], Karoline Kuchenbaecker[8], Jean-Baptiste Pingault[1,9*]

*Corresponding author: Prof. Jean-Baptiste Pingault, j.pingault@ucl.ac.uk*

## Affiliations

1. Department of Clinical, Educational and Health Psychology, University College London, London, United Kingdom
2. Institute of Cardiovascular Science, University College London, London, United Kingdom
3. The National Institute for Health Research University College London Hospitals Biomedical Research Centre, University College London, London, UK
4. Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
5. Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
6. Institute of Health Informatics, University College London, London, United Kingdom
7. Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL GOS Institute of Child Health, University College London, London, United Kingdom
8. Division of Psychiatry, University College London, London, United Kingdom
9. Social Genetic and Developmental Psychiatry, King's College London, London, United Kingdom

# Abstract

Major depressive disorder (MDD) treatments have limited efficacy and target few mechanisms, highlighting the need for innovative drug discovery. Drugs targeting genetically supported proteins are 2.6 times more likely to succeed in drug development. Here, we use genetic methods to identify and prioritise MDD drug targets, leveraging genome-wide association study (GWAS) summary statistics from >525,000 MDD cases. We derived exposure data from 10 GWAS measuring protein quantitative trait loci (pQTLs) and gene expression levels (eQTLs) in blood, cerebrospinal fluid, and brain tissues. We performed *cis*-Mendelian randomisation (MR) on 3,469 druggable targets (genes encoding proteins targeted by existing compounds or experimentally predicted to be druggable). To strengthen causal inference, we implemented robust MR estimators, colocalisation, external replication, and assessed directional consistency across tissues. We integrated MR effect directions with drug mechanisms and clinical annotations to infer potential therapeutic effects. Validation analyses showed that 82% of drugs approved for depression/anxiety had ≥1 significant MR target, compared to 51% for compounds in clinical trials. For repurposing, we prioritised 54 targets of compounds developed for other conditions with estimated beneficial effects on MDD (e.g., an inhibitor for a risk-increasing target). Ten high-priority targets of brain-penetrating compounds included ACE and NISCH (cardiovascular drugs), NDUFA2, NDUFB6, and NDUFS1 (metformin), CDK4, NTRK3, and MET (oncology inhibitors), and GLS and NOS2 (enzyme inhibitors). We found genetic evidence for established and novel MDD targets across the drug development pipeline. Novel targets point to mechanisms beyond monoaminergic systems, most with approved drugs for other conditions, offering immediate repurposing opportunities.

## Introduction

Major depressive disorder (MDD) is common and a leading cause of years lived with disability globally [1]. Current pharmacological treatments are ineffective for many with MDD, with only one-third of patients reaching remission after first-line antidepressant treatment [2]. Furthermore, 28-40% of patients are classified as having treatment-resistant depression, defined as not remitting after the prescription of two or more antidepressants [2,3]. Currently approved drugs target a narrow range of therapeutic mechanisms, with most antidepressants acting on monoaminergic neurotransmitter systems [4]. The lack of novel pharmacological treatments for MDD highlights the pressing need for innovative strategies to facilitate efficient drug discovery.

Human genetics offers a promising avenue to guide the development of pharmacological treatments. Drugs acting on targets with supporting human genetic evidence are 2.6 times more likely to succeed in drug discovery pipelines and progress into clinical practice than those without [5–7]. This is reflected in recent FDA approvals: 63% of drugs approved in the past decade had genetic support [8]. Given that genes encode proteins, which constitute over 90% of drug targets, genetic methods can identify disease-associated protein targets suitable for repurposing existing drugs or for novel development opportunities [9,10]. To accelerate discovery and repurposing, an efficient strategy involves focusing on the 'druggable genome' rather than all protein-coding genes, reducing the multiple testing burden [9–11]. The druggable genome comprises genes encoding proteins targeted by drugs that are already approved, those at the clinical stage of drug development, or those potentially druggable based on experimental evidence [9].

Mendelian randomisation (MR) enables scanning of the druggable genome by using genetic variants as instruments to estimate the effect of altering each drug target's activity on disease risk [12]. For each target protein, genetic variants selected as instruments lie within and around the gene encoding that protein (*cis*-region) [11]. These instruments are

50 associated with individual variation in a molecular trait in a given tissue, including changes in
51 protein values or mRNA expression [10]. *Cis*-MR leverages data from genome-wide
52 association studies (GWAS) to obtain the effects of each selected variant on both the
53 exposure (target protein activity) and the outcome (MDD). To infer exposure-outcome causal
54 effects, MR assumes that variant effects on the outcome operate through the exposure and
55 are independent of confounders [12]. Under these assumptions, a significant MR estimate
56 suggests that modulating the protein corresponding to the instrumented *cis*-region may
57 influence the disease process, making it a candidate drug target for that outcome [10,12].
58 MR has key advantages for identifying drug targets. First, the random assortment of genetic
59 variants at conception mimics treatment allocation in randomised controlled trials,
60 strengthening causal inference regarding target effects on disease outcomes [13]. Second,
61 MR provides the direction of effect to infer whether activating or inhibiting a target would
62 mitigate disease risk [14]. The effect direction can then be combined with pharmacological
63 data on existing drugs to identify target-compound pairs with aligned mechanisms, thus
64 directly aiding repurposing [14,15].

65 To conduct drug target MR, a large-scale GWAS of the disease outcome of interest is
66 fundamental. The latest Psychiatric Genomics Consortium (PGC) Phase 3 MDD GWAS
67 offers unprecedented opportunities in this regard. The meta-analysis found 635 genomic loci
68 associated with MDD, of which 293 are novel [16]. Alongside identifying over 300 high-
69 confidence genes and associated pathways, the study performed drug target enrichment
70 analyses [16]. Using sets of genes encoding drug targets and grouping them by drug classes
71 showed that antidepressant and antipsychotic classes were enriched for MDD-associated
72 variants [16]. Additionally, 18 individual compounds approved mainly for indications other
73 than depression were enriched, including antipsychotics, treatment for cancer, anxiety
74 (pregabalin), and narcolepsy (modafinil) [16]. However, as noted by the authors, enrichment
75 analysis is not directional and cannot distinguish whether implicated compounds might
76 increase or decrease MDD symptoms [16]. Enrichment of established antidepressant drug

class alongside potential repurposing opportunities underscores the value of this large-scale GWAS dataset for a detailed and directional drug target MR interrogation.

While initial druggable genome *cis*-MR applications to MDD have provided a foundation by inferring directional effects [17,18], opportunities remain to advance and strengthen this approach. The current study addresses this by introducing an integrated approach that leverages several methodological advances to robustly identify and prioritise targets. First, we enhance statistical power by using the latest large-scale PGC Phase 3 MDD GWAS [16]. Second, we expand the scope of the druggable genome beyond established targets to include novel candidates supported by experimental evidence of druggability. Third, we evaluate target effects across blood, cerebrospinal fluid (CSF), and multiple brain regions, beyond previous brain-restricted analyses [17,18]. Finally, our framework strengthens the validation of genetic evidence by employing multiple robust MR estimators, colocalisation, external replication, and tissue-specific directional consistency.

To identify a tractable set of high-priority targets from our *cis*-MR findings for experimental and clinical validation, we integrate genetic evidence with clinical and pharmacological data. Such a framework has been applied to other non-psychiatric complex diseases, evaluating genetic robustness, clinical relevance, and pharmacological properties of target-compound pairs [14,15,19]. These studies integrated target effect directions with pharmacological mechanisms and clinical profiles of existing drugs [14,15,19]. Aligning the genetically estimated benefit of modulating a target with the mechanisms of drugs approved for other indications can identify high-confidence repurposing candidates [14,15]. The approach was validated by genetically recapitulating established pharmacological treatments for diseases, known as 'positive controls' [14,15]. Applying this framework to MDD is particularly pertinent, where therapeutic mechanisms are thought to be complex [4]. Addressing a gap in prior MDD drug target MR investigations [17,18], we also evaluate established antidepressant targets as positive controls to benchmark analyses and strengthen prioritisation of novel candidates.

We applied an integrated genetic and pharmacological framework to systematically identify and prioritise MDD drug targets within the druggable genome. First, we aimed to identify targets using *cis*-MR and assess the genetic robustness of findings through multiple sensitivity analyses. Second, we sought to validate our approach using established MDD target-compound pairs as positive controls. Third, we aimed to characterise repurposing opportunities by integrating genetic effects with drug mechanisms of action and clinical annotations (e.g., primary indications and side effects).

111 # Methods

112 ## Outcome and exposure data

113 ### *GWAS summary statistics*

114 For our outcome, we used summary statistics from the PGC MDD phase 3 GWAS meta-
115 analysis (525,197 cases and 3,362,335 controls) of European genetic ancestry (PGC MDD-
116 3) [16]. We derived exposure genetic instruments from 10 GWAS of protein or transcript
117 values measured in blood [20–22], cerebrospinal fluid (CSF) [23], or multiple brain regions
118 [24,25] (Supplementary Table 1). These genetic variants are quantitative trait loci (QTLs)
119 strongly associated with changes in protein levels (pQTLs) or mRNA expression (eQTLs) in
120 each tissue [10]. To maximise protein coverage and enable cross-platform validation [26],
121 blood plasma proteomic data was derived from two pQTL GWAS measured using different
122 protein assay platforms: deCODE (SomaScan) and UK Biobank Pharma Proteomics Project
123 (Olink; Supplementary Methods) [20,21]. We analysed each protein/transcript GWAS
124 separately (hereafter referred to as a 'panel').

125 ### *Drug target data*

126 We selected 3,652 genes encoding drug target proteins for *cis*-MR analysis using
127 hierarchical druggability assessments from Open Targets [27]. We included all targets with
128 clinical trial evidence from ChEMBL [28], with the following hierarchy: approved drugs
129 (phase IV, already ‘drugged’), advanced clinical development (phases II-III), and early
130 clinical development (phase I). For targets with only experimental evidence (i.e. potentially
131 druggable), we retained those within the top tier of experimental quality assessments from
132 Open Targets hierarchical scoring (Supplementary Methods) to incorporate targets with
133 promising druggability potential.

## Primary Mendelian Randomisation (MR) analysis

We used purpose-built Python packages for *cis*-MR analyses [19]. We selected genetic variants as instruments with minor allele frequencies (MAF) > 0.01, located within 200kb of the *cis*-gene [29], and with exposure GWAS p-value < $1x10^{-6}$. We applied MR Steiger filtering to minimise reverse causation by removing variants with a greater effect on the outcome than on the exposure. Variants were clumped (linkage disequilibrium (LD) $R^2$ = 0.4), and remaining instrument correlations were accounted for by generalised least squares modelling. LD reference matrices were derived from a random subset of 5,000 UK Biobank participants of European genetic ancestry [30]. We employed the Wald ratio estimator (MR-Wald) for targets instrumented by a single genetic variant, and the generalised least squares implementation of the inverse-variance weighted estimator (MR-IVW), allowing for correlated instruments for targets with multiple variants [31]. To mitigate potential horizontal pleiotropy in our IVW analysis, we applied heterogeneity-based pruning of variants with large leverage (>3 times the mean) or outlier statistics (chi-square >11) [19,32]. We implemented fixed-effects IVW for targets with <4 IVs and random-effects for ≥4 [33,34].

A total of 3,469 targets of the 3,652 in the druggable genome had instrument(s) that passed our filtering criteria. We applied Bonferroni correction ($p<3.9\times10^{-6}$), accounting for 12,794 MR-IVW/-Wald tests across 10 panels spanning blood, brain and CSF. We used the total number of tests rather than unique targets tested, as most targets (94%) were tested more than once across panels (Supplementary Table 2).

## Sensitivity analyses and target annotation

### *MR-IVW robustness*

We employed three robust methods, with different assumptions about instrument validity [35], across four models: generalised least squares implementation of MR-Egger with and without heterogeneity-based pruning [36], contamination mixture [37], and weighted median

160 methods [38] (Supplementary Methods). We applied Bonferroni correction ($p<7.2\times10^{-5}$) for
161 693 significant IVW estimates from our primary analysis that we sought to test with robust
162 MR. Robust MR estimates that were significant and directionally consistent with IVW
163 estimates for that target provided stronger evidence for the validity of our causal estimates
164 [35]. Targets with significant but inconsistent directional effects across IVW and robust
165 estimators were deprioritised.

166 *External pQTL replication*

167 We performed external replication of targets significant in our primary *cis*-MR analyses in
168 independent QTL datasets, focusing on panels with a matching molecular phenotype
169 modality (i.e. pQTL) and tissue type (i.e., blood or brain) to our discovery panels
170 (Supplementary Methods and Supplementary Table 3). We defined successful replication as
171 a significant MR-IVW/-Wald effect in the replication panel that was directionally consistent
172 with the discovery panel effect estimate. The eQTL targets were not tested for external
173 replication as they were derived from large-scale meta-analyses for which comparably well-
174 powered independent datasets were unavailable.

175 *Colocalisation*

176 We performed colocalisation analyses for each significant MR-IVW/-Wald target in a given
177 QTL panel to evaluate whether molecular traits (pQTL/eQTL) and MDD share causal
178 variants. We used the *coloc* R package and the *'coloc.abf'* function (Supplementary
179 Methods) [39] with a posterior probability threshold of ≥ 0.8 to indicate strong evidence.
180 Strong evidence for PPH4 indicates a shared causal variant between the molecular trait and
181 MDD offering triangulation of evidence alongside *cis*-MR [29,40]. Conversely, strong PPH3
182 evidence indicates distinct causal variants for each trait, suggesting potential violations of
183 MR assumptions due to, for example, linkage disequilibrium, or pleiotropic pathways through
184 neighbouring genes [29,40].

185 *Estimated therapeutic relevance*

186 To evaluate the therapeutic relevance of drug targets with significant *cis*-MR effects, we
187 integrated our genetic findings with drug mechanisms of action data from ChEMBL [28]. We
188 estimated whether existing compounds targeting that protein would act in a potentially
189 beneficial direction based on the MR-IVW/-Wald effect direction (Supplementary Methods).
190 We classified therapeutic directional effects as 1) 'beneficial', where the drug's mechanism
191 mitigates the risk-increasing effect of the target on MDD (e.g., an inhibitor for a target whose
192 increased expression increases MDD risk); 2) 'adverse', the drug's mechanism is in the
193 same direction as the target's risk-increasing effect; or 3) 'unknown', the relationship could
194 not be classified (e.g., for mechanisms that do not specify inhibition or activation).

195 *Known depression-related drug effects*

196 We extracted known depression-related therapeutic applications or side effects for
197 compounds targeting significant MR-IVW/-Wald proteins. We classified drug effects using
198 core depression terms (MDD, depression, apathy, mood, anxiety, suicidality) and broader
199 depression-relevant terms encompassing related psychiatric and somatic symptoms
200 (Supplementary Methods). Drug effects data were extracted from databases of drugs
201 licensed in the UK (primary therapeutic indications, side effects, cautions, and
202 contraindications) and ChEMBL (primary compound indications in clinical trial phases I-IV)
203 [28]. Depression-related clinical effects, including adverse effects, suggest biological
204 relevance. Targets can be modulated by drugs with different mechanisms (activators or
205 inhibitors), allowing for the development of novel drugs with beneficial effects. Furthermore,
206 as documented in databases of medications licensed in the UK, approved antidepressants
207 have reported psychiatric side effects, including mood changes and anxiety. Thus,
208 depression-related symptoms as side effects do not necessarily preclude therapeutic
209 potential.

210 ## Target prioritisation

211 We evaluated significant MR-IVW/-Wald drug targets from our primary analysis by
212 considering evidence for each target across assessments of genetic robustness and
213 therapeutic potential (**Figure 1**).

214 ### *Genetic robustness assessment*

215 To evaluate genetic evidence, we incorporated four assessments. First, we favoured targets
216 with consistent directional *cis*-MR effects across ≥2 discovery panels within the same tissue
217 type (brain or blood). We excluded blood pQTL targets with directionally opposite *cis*-MR
218 effects between discovery panels using different protein assay platforms, indicating technical
219 artefacts in protein measurement (Supplementary Methods). Second, we favoured targets
220 with robust MR estimates that aligned with the primary MR-IVW effect direction and
221 excluded those with directional disagreement. Third, we prioritised targets with PPH4
222 colocalisation evidence, excluding those with PPH3 evidence. Fourth, we prioritised pQTL
223 targets with external replication. Not all targets had sufficient data or statistical power to be
224 evaluated by each of these criteria. We therefore prioritised targets meeting ≥1 of these
225 criteria, alongside therapeutic potential.

226 ### *Therapeutic potential assessment*

227 We focused on identifying repurposing candidates, defined as targets of drugs approved for
228 the treatment of non-psychiatric conditions. We also considered targets of compounds tested
229 in clinical trials for indications other than depression or anxiety. We evaluated clinical
230 relevance by identifying targets with compounds developed for other conditions that showed
231 depression-related drug effects. We integrated our therapeutic beneficial compound analysis
232 by prioritising targets with at least one compound that has mechanisms acting in a direction
233 that would oppose the target risk-increasing effect indicated by our MR results.

234 *Final prioritisation criteria*

235 Among significant targets from our primary *cis*-MR analysis, we prioritised targets meeting
236 two criteria: 1) either ≥1 genetic robustness evidence or targeted by compounds showing
237 depression-related drug effects, and 2) targeted by ≥1 compound(s) with estimated
238 beneficial therapeutic direction. We then categorised prioritised targets by tissue expression
239 (brain-only, blood-only or brain and blood). We investigated brain-only targets as high-
240 priority given the neurobiological basis of MDD and that tissue-specific targets may produce
241 fewer off-target effects than those ubiquitously expressed [41]. Among prioritised brain-only
242 targets, we further defined high-priority targets as those meeting both of the following criteria
243 through literature searches: 1) blood-brain barrier permeability of estimated beneficial
244 compounds, and 2) the target's role in depression-relevant pathophysiological mechanisms.
245 This included literature on the target function in relevant biological processes and evidence
246 for antidepressant-like effects of beneficial compounds or target modulation in animal
247 models or human studies.

## 248 Positive control analysis

249 We identified positive controls (PCs), also known as genetic rediscoveries of known drug-
250 target mechanisms, using drug effects data from ChEMBL and databases of drugs licensed
251 in the UK [28]. We selected targets of drugs with primary indications for depression and/or
252 anxiety and classified them as approved PC targets (our primary positive controls, targeted
253 by drugs in phase IV) and clinical trial PC targets (our secondary positive controls, targeted
254 by compounds in clinical trial phases I-III). We included anxiety due to the high comorbidity,
255 treatment and genetic overlap between anxiety disorders and MDD, with genetic correlations
256 approaching unity (~0.9) [42–44]. As a single compound can act on multiple targets, we also
257 analysed our results at the compound level (Supplementary Materials). We conducted
258 enrichment analyses to assess whether our *cis*-MR approach identified known drug targets
259 for depression. We separately compared significance rates in brain and blood tissues of 1)

260 approved PC targets versus all other targets, and 2) clinical trial PC targets versus all other
261 non-PC targets. An odds ratio (OR) > 1 indicated higher odds of PC targets among
262 significant results (Supplementary Methods).

263

# Results

## Overview

Our primary *cis*-MR analysis identified 564 unique drug targets (of 3,469 tested) significantly associated with MDD across at least one of ten panels of protein or transcript values measured in blood, brain, and CSF (see Supplementary Tables 4-13 for genetic results in each panel). We evaluated significant targets by integrating evidence for genetic robustness and therapeutic potential (**Figure 1** and Supplementary Table 14). Target-level aggregated results from all analyses for each of the 564 significant targets are in Supplementary Table 15.

## Positive control (PC) analysis

Our *cis*-MR analysis demonstrated stronger genetic support for compounds in clinical trial phase IV for depression and anxiety (approved positive controls (PC)) than those in clinical trial I-III (clinical trial PCs). At the drug level, 50/61 (82%) approved PCs showed at least one significant MR target effect on MDD, compared to 86/169 (51%) for clinical trial PC compounds (Supplementary Tables 16-18). Of the approved PC drugs with significant targets, most showed estimated beneficial mechanisms of action. Specifically, 27 drugs (54%) had targets with exclusively beneficial effects (where drug mechanisms oppose target MDD risk directions indicated by MR), while 13 drugs (26%) with multiple targets showed mixed effects (i.e. beneficial on some targets, adverse on others). Only 4 (8%) exhibited exclusively adverse effects, and 6 (12%) had unknown directionality. For compounds undergoing clinical trials, 29 (33.7%) showed beneficial mechanisms, 24 (27.9%) had mixed effects, 15 (17.4%) demonstrated adverse effects, and 18 (20.9%) had unknown directionality. **Table 1** presents results for targets of key positive controls with significant MR effects and estimated therapeutic directions that align with their known clinical efficacy for MDD and/or anxiety.

289 At the target-level, we found significant enrichment of targets of approved PC compounds in
290 brain tissues (OR=1.97, 95% CI=1.11-3.49, p=0.018; Supplementary Table 19). Approved
291 PC targets had a 1.7-fold higher rate of significant MR estimates (18.8%) in the brain
292 compared to other targets (10.5%). Notably, the aforementioned compound-level rate (82%)
293 was higher because most drugs act on multiple targets, and compounds required only one of
294 those targets to be significant to be counted.

295 Targets of clinical trial PCs showed similar brain-specific enrichment (OR=1.54, 95%
296 CI=1.02-2.30, p=0.036). Enrichment was not significant in blood tissues for either approved
297 PC targets (OR=1.81, 95% CI=0.75-4.35, p=0.289) or clinical trial PC targets (OR=1.10,
298 95% CI=0.60-2.03, p=0.756). *Cis*-MR evidence for positive controls in brain tissues supports
299 the biological validity of our approach, aligning with the neurobiological aetiology of MDD
300 and with established pharmacological interventions targeting neurotransmitter systems and
301 neural circuitry [45].

## 302 Prioritisation of novel targets for repurposing

303 We identified 523 drug targets beyond those currently used or explored in depression
304 treatment. Following our systematic prioritisation framework (**Figure 1**), 216 targets met
305 criteria for genetic robustness evidence or clinical relevance, of which 54 were prioritised
306 due to being targeted by compounds with estimated beneficial therapeutic directions for
307 MDD (Supplementary Table 15). Tissue expression patterns of prioritised targets included
308 four found in both brain and blood panels, 31 brain-only targets, and 19 blood-only targets.
309 Of the 31 targets exhibiting brain-specific effects, 10 met our high-priority criteria with blood-
310 brain barrier-penetrant compounds and supporting literature for depression-relevant
311 mechanisms (**Table 2** and Supplementary Table 20).

312 # Discussion

313 We identified novel drug targets and immediate repurposing opportunities for MDD by
314 triangulating genetic evidence and clinical data. Our integrated framework strengthens
315 causal inference in target identification, guiding repurposing. The target-compound pairs we
316 prioritise span MDD drug development stages. These include long-standing antidepressants,
317 recently approved treatments, repurposing compounds in MDD clinical trials or with early
318 clinical evidence not yet formally tested for MDD treatment, and candidates with strong
319 preclinical evidence.

320 ## Genetic validation through established targets and mechanisms

321 Our findings suggest genetic evidence informs clinical success in MDD drug development,
322 with a higher rate of significant targets for phase IV positive control drugs (82%) versus
323 earlier phases I-III compounds (51%). We corroborate broader findings that genetically
324 supported compounds for complex traits are more likely to be approved [7]. Additionally,
325 targets of positive control compounds showed enrichment in brain tissues, validating our
326 focus on brain targets for repurposing.

327 For monoaminergic targets of approved MDD treatments, risk-increasing expression of
328 *SLC6A4* (encoding the serotonin transporter), *SLC6A3* (dopamine transporter), and *DRD2*
329 (dopamine D2 receptor) aligned with the established therapeutic inhibitory mechanisms of
330 antidepressants, bupropion, and antipsychotics, respectively. Genetic evidence for DRD2
331 antagonism was consistent across brain regions, including the basal ganglia, aligning with its
332 role in reward processing [46]. By specifically implicating DRD2 antagonism, we provide
333 directional insight into the PGC MDD-3 GWAS findings that identified the *DRD2* gene as the
334 strongest gene-based association and antipsychotic compound enrichment [16]. Beyond
335 monoaminergic signalling in MDD, we also found genetic support for anxiety medications,
336 reflecting the high comorbidity and genetic overlap between these disorders [42–44]. For
337 example, multiple calcium channel subunits showed significant effects in the brain, aligning

338 with pregabalin's efficacy in depression-anxiety comorbidity [47], and the PGC MDD-3
339 finding that pregabalin was among the top-enriched compounds [16].

340 Positive control compounds with multiple targets showed both exclusively beneficial and
341 mixed therapeutic effects. For the dual-action tricyclic antidepressant Amoxapine, genetic
342 effects aligned with therapeutic benefits for both serotonergic (via SLC6A4 inhibition) and
343 dopaminergic (via DRD2 antagonism) signalling. Conversely, for esketamine, genetic effects
344 aligned with therapeutic benefits of inhibiting GRIN1 and GRIN2D, but adverse for GRIN2A,
345 consistent with mixed therapeutic and side effect profiles for different NMDA receptor
346 subunits [48,49]. Similar patterns were observed among GABAA receptor subunits targeted
347 by anxiolytic benzodiazepines. Target-specific genetic effects suggest which receptor
348 subtypes may drive therapeutic benefits versus contribute to side effects [48–50]. Our
349 findings could potentially inform the development of more selective compounds with
350 improved efficacy-to-side-effect profiles for MDD.

## 351 Cardiovascular and metabolic repurposing compounds

352 Our genetic evidence supports repurposing of multiple types of cardiovascular and metabolic
353 system drugs for MDD, from different stages in the repurposing pipeline. For pentoxifylline, a
354 PDE inhibitor approved for vascular disease and tested in depression clinical trials [51–54],
355 we found four beneficial PDE6 and PDE3 subunits and one adverse, guiding subtype-
356 specific targeting to improve efficacy [55]. A meta-analysis of Phase II trials found adjunctive
357 pentoxifylline significantly improved depressive symptoms [56]. Among compounds with
358 preliminary clinical evidence and yet to be formally evaluated in MDD clinical trials, *ACE*
359 gene expression showed a risk-increasing effect in cortical tissue. BBB-penetrant ACE
360 inhibitors like captopril used in the treatment of hypertension have demonstrated animal
361 model antidepressant-like effects and mental health benefits as a secondary outcome in
362 clinical trials [57,58] potentially by reducing oxidative stress and neuroinflammation while

363 enhancing serotonergic signalling [59]. Both PDE inhibitors and ACE inhibitors are widely
364 used and well-tolerated in cardiovascular medicine, adding to their potential for repurposing.

365 We identified risk-increasing effects on MDD for Complex I subunit cortical expression
366 (*NDUFA2*, *NDUFB6*, *NDUFS1* genes), aligning with the inhibitory mechanism of metformin
367 on these targets, a type 2 diabetes medication. This complements the identification of
368 another metformin gene encoding target, *NDUFAF3*, as a novel MDD-associated gene [60].
369 Metformin exhibits antidepressant and anxiolytic-like effects in animal models [61,62] and is
370 associated with a decreased risk of depression in observational case-control studies [63].
371 Whilst one phase III trial demonstrated metformin's efficacy in treatment-resistant bipolar
372 depression [64], the only published clinical trial formally investigating metformin for MDD
373 treatment as a primary outcome was retracted [65]. Given our genetic evidence alongside
374 preclinical and observational support, prioritising metformin for clinical trials with MDD as a
375 primary outcome is warranted.

376 Preclinical evidence supports the potential of antihypertensive imidazoline $I_1$ agonists for
377 MDD. We found mixed effects of *NISCH* (encoding Nischarin, the proposed $I_1$ receptor)
378 across brain regions, likely reflecting context-dependent roles in neuroinflammation and
379 neural plasticity [66,67]. $I_1$ agonist agmatine may be an endogenous antidepressant [68],
380 with compensatory increased brain levels during stress and antidepressant-like effects in
381 rodents [69–71] alongside *NISCH* amygdala downregulation [72]. SSRI efficacy may be
382 partially mediated by $I_1$ activation [73,74]. Consistent with our risk-increasing brain effects,
383 Nischarin was elevated in postmortem prefrontal cortex of MDD patients but lower in those
384 taking antidepressants [75]. These findings establish Nischarin as a relevant MDD target
385 through potential involvement in stress-depression pathways and antidepressant action.

386 ## Cancer repurposing compounds

387 Among our prioritised novel targets were three proteins inhibited by BBB-penetrant cancer
388 drugs, with plausible roles in neural function. CDK4 showed mixed directional effects across
389 five brain regions, reflecting diverse neural functions regulating neurogenesis [76], neuronal
390 activity [77] and synaptic plasticity [78]. *NTRK3* encodes the receptor for neurotrophin-3,
391 which modulates monoaminergic transmission, BDNF expression and HPA axis function
392 [79]. We corroborate the PGC MDD-3 identification of *NTRK3* as a high-confidence MDD
393 gene [16] whilst providing novel directional insights by identifying inhibitors to counteract the
394 risk-increasing effect of NTRK3. *MET* encodes the MET hepatocyte growth factor receptor,
395 involved in regulating neuroplasticity, neurotrophic pathways, and inflammation [80].
396 Approved inhibitors for all three targets exhibit psychiatric side effects, supporting their
397 neuropsychiatric relevance [81–83]. However, the CDK4-selective inhibitor abemaciclib
398 demonstrates the potential for an improved nervous system safety profile when repurposing
399 cancer drugs for MDD, with fewer psychiatric side effects than less selective alternatives
400 [83]. Further investigations of CDK4, NTRK3 and MET inhibitors in MDD are warranted, such
401 as dose-ranging studies or selective compound development to optimise efficacy while
402 minimising side effects.

403 ## Early-stage drug development compounds

404 We identified two enzyme targets inhibited by experimental compounds yet to be clinically
405 approved for any indication or tested in MDD clinical trials, representing opportunities
406 beyond the repurposing of approved medications. Inhibiting GLS (glutaminase) offers a
407 mechanistically distinct approach to glutamatergic modulation compared to approved
408 depression compounds. While NMDA antagonists (e.g. esketamine) block glutamate
409 receptor signalling, glutaminase inhibition reduces glutamate production in activated
410 microglia, directly limiting excitotoxicity and neuroinflammation [84,85]. The novel BBB-
411 penetrant glutaminase inhibitor JHU-083 demonstrates antidepressant-like effects in animal

412 models while minimising peripheral side effects as a pro-drug [84,85]. Similarly, inhibition of
413 inducible nitric oxide synthase (iNOS, encoded by *NOS2*) targets glial-induced
414 neuroinflammation [86,87]. Unlike other NOS isoforms, iNOS offers temporal and cell-type-
415 specificity to reduce neuroinflammation without affecting normal NO signalling [86,87].
416 Selective iNOS inhibition in rodents exhibits antidepressant-like effects [88,89] and
417 attenuates stress-induced anxiogenic effects [90]. To our knowledge, we provide the first
418 human genomic evidence for these preclinical compounds, highlighting the potential for
419 novel MDD therapeutics targeting neuroinflammatory pathways.

## 420 Limitations and future directions

421 Whilst we prioritised drugged targets for rapid translation and included high-quality
422 experimental targets beyond prior studies [17,18], other pQTL/eQTLs may in the future
423 become therapeutically viable [9]. Genetic effect directions not aligning with known
424 therapeutic mechanisms may reflect differences between lifelong genetic versus acute
425 pharmacological effects [91], tissue [10] or cell-specific effects [29]. Furthermore, c*is*-MR
426 examines the effects of individual proteins, however, proteins function within complex
427 pathways [92], challenging estimation of therapeutic effects from single-target modulation.
428 Polypharmacological effects can trigger broader network responses and compensatory
429 mechanisms [92,93]. While *cis*-MR reduces the risk of horizontal pleiotropy and we applied
430 robust MR estimators, it cannot be entirely ruled out [10]. Only 11% of targets had sufficient
431 power for colocalisation, which requires strong *cis*-region GWAS associations in both traits
432 [94]. Our analysis of European-associated ancestry data may limit generalisability to other
433 populations [95]. Experimental validation and clinical studies are needed to confirm the
434 therapeutic potential of novel targets, with research required in globally representative
435 populations and diverse biological contexts.

436 MDD heterogeneity challenges translating genetically supported targets and compounds into
437 treatments. Despite genetic evidence from our study and previous work [18], CRHR1

438 antagonists targeting stress-dysregulation have failed in depression clinical trials [96].
439 Similarly, anti-inflammatory drug clinical trials have largely been unsuccessful [97]. These
440 failures may stem from a ‘one-size fits all’ approach, obscuring therapeutic effects for a
441 subset of patients [97,98]. Future work could explore genetically supported compounds
442 through patient stratification, matching treatments to MDD subtypes e.g., stress-
443 dysregulation or inflammation-driven symptoms [97,98].

## 444 Conclusions

445 Our genetically informed approach corroborated established MDD targets while identifying
446 novel therapeutic opportunities beyond traditional monoaminergic mechanisms. Several
447 novel targets have approved drugs for other indications with established safety profiles and
448 BBB-penetration, offering opportunities for immediate clinical evaluation.

## Acknowledgements

This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (I-IRISK grant agreement No. 863981). AFS is supported by BHF grants PG/18/5033837, PG/22/10989, the UCL BHF Research Accelerator AA/18/6/34223. AFS received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. SB is supported by the Great Ormond Street Hospital Children's Charity. This work was funded by UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee EP/Z000211/1, by the UKRI/NIHR Multimorbidity fund Mechanism and Therapeutics Research Collaborative MR/V033867/1, and by the Rosetrees Trust. The authors acknowledge the use of the UCL Myriad High Performance Computing Facility (Myriad@UCL), and associated support services, in the completion of this work. This research has been conducted using the UK Biobank Resource under application number 12113. We are grateful to the UK Biobank participants. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government, and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. We thank the research participants and employees of 23andMe, Inc. for their contribution to the GWAS summary data used in this study.

## Ethical approval

The UK Biobank has ethical approval from the North West Multi-centre Research Ethics Committee as a Research Tissue Bank approval (REC reference: 21/NW/0157).

## Data availability

GWAS summary statistics for MDD are available from the Psychiatric Genomics Consortium at https://pgc.unc.edu/for-researchers/download-results/. GWAS summary statistics

474 including 23andMe data require an approved application through 23andMe available to
475 qualified researchers under an agreement with 23andMe that protects the privacy of the
476 23andMe participants (visit https://research.23andme.com/dataset-access/). UK Biobank
477 data are available through application at https://www.ukbiobank.ac.uk/enable-your-
478 research/apply-for-access/. Open Targets tractability data can be downloaded from
479 http://ftp.ebi.ac.uk/pub/databases/opentargets/platform/latest/input/target/tractability/. QTL
480 datasets are available from: Blood plasma pQTL data: deCODE
481 (https://www.decode.com/summarydata/), UKB-PPP
482 (https://www.synapse.org/#!Synapse:syn51364943/), INTERVAL
483 (http://www.phpc.cam.ac.uk/ceu/proteins/), and Gudjonsson
484 (https://www.ebi.ac.uk/gwas/publications/35078996). Brain pQTL data: ROSMAP and
485 Banner (https://www.synapse.org/#!Synapse:syn24172458). CSF pQTL data: Yang
486 (https://dss.niagads.org/datasets/ng00102/). Blood eQTL data: eQTLGen
487 (https://www.eqtlgen.org/). Brain eQTL data: MetaBrain (https://www.metabrain.nl/).

## 488 Conflicts of interest

489 The authors have nothing to disclose.

490 ## References


491 1. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12
492 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the
493 Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–50.

494 2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation
495 of outcomes with citalopram for depression using measurement-based care in STAR*D:
496 implications for clinical practice. Am J Psychiatry. 2006;163:28–40.

497 3. Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. Switching
498 antidepressant class does not improve response or remission in treatment-resistant
499 depression. J Clin Psychopharmacol. 2011;31:512–6.

500 4. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for
501 refining future treatment approaches. Lancet Psychiatry. 2017;4:409–18.

502 5. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be
503 approved? Revised estimates of the impact of genetic support for drug mechanisms on the
504 probability of drug approval. PLoS Genet. 2019;15:e1008489.

505 6. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human
506 genetic evidence for approved drug indications. Nat Genet. 2015;47:856–60.

507 7. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on
508 clinical success. Nature. 2024;629:624–9.

509 8. Rusina PV, Falaguera MJ, Romero JMR, McDonagh EM, Dunham I, Ochoa D. Genetic
510 support for FDA-approved drugs over the past decade. Nat Rev Drug Discov. 2023;22:864.

511 9. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable
512 genome and support for target identification and validation in drug development. Sci Transl
513 Med [Internet]. 2017;9. Available from: http://dx.doi.org/10.1126/scitranslmed.aag1166

514 10. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al.
515 Genetic drug target validation using Mendelian randomisation. Nat Commun. 2020;11:3255.

516 11. Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, et al. Improving the
517 odds of drug development success through human genomics: modelling study. Sci Rep.
518 2019;9:18911.

519 12. Daghlas I, Gill D. Mendelian randomization as a tool to inform drug development using
520 human genetics. Cambridge Prisms: Precision Medicine. 2023;1:e16.

521 13. Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel
522 approach for the prediction of adverse drug events and drug repurposing opportunities. Int J
523 Epidemiol. 2017;46:2078–89.

524 14. Gordillo-Marañón M, Zwierzyna M, Charoen P, Drenos F, Chopade S, Shah T, et al.
525 Validation of lipid-related therapeutic targets for coronary heart disease prevention using

526 human genetics. Nat Commun. 2021;12:6120.

527 15. Storm CS, Kia DA, Almramhi MM, Bandres-Ciga S, Finan C, International Parkinson's
528 Disease Genomics Consortium (IPDGC), et al. Finding genetically-supported drug targets for
529 Parkinson's disease using Mendelian randomization of the druggable genome. Nat
530 Commun. 2021;12:7342.

531 16. Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium.
532 Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell
533 types and pharmacotherapies. Cell [Internet]. 2025; Available from:
534 http://dx.doi.org/10.1016/j.cell.2024.12.002

535 17. Liu J, Cheng Y, Li M, Zhang Z, Li T, Luo X-J. Genome-wide Mendelian randomization
536 identifies actionable novel drug targets for psychiatric disorders. Neuropsychopharmacology.
537 2023;48:270–80.

538 18. Li Y, Dang X, Chen R, Teng Z, Wang J, Li S, et al. Cross-ancestry genome-wide
539 association study and systems-level integrative analyses implicate new risk genes and
540 therapeutic targets for depression. Nat Hum Behav. 2025;9:806–23.

541 19. Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, et al.
542 Druggable proteins influencing cardiac structure and function: Implications for heart failure
543 therapies and cancer cardiotoxicity. Sci Adv. 2023;9:eadd4984.

544 20. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir
545 EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat
546 Genet. 2021;53:1712–21.

547 21. Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma
548 proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329–
549 38.

550 22. Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Large-scale
551 cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that
552 regulate blood gene expression. Nat Genet. 2021;53:1300–10.

553 23. Yang C, Farias FHG, Ibanez L, Suhy A, Sadler B, Fernandez MV, et al. Genomic atlas of
554 the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological
555 disorders. Nat Neurosci. 2021;24:1302–12.

556 24. Robins C, Liu Y, Fan W, Duong DM, Meigs J, Harerimana NV, et al. Genetic control of
557 the human brain proteome. Am J Hum Genet. 2021;108:400–10.

558 25. de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen C-Y, et al. Brain expression
559 quantitative trait locus and network analyses reveal downstream effects and putative drivers
560 for brain-related diseases. Nat Genet. 2023;55:377–88.

561 26. Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et
562 al. Large-scale plasma proteomics comparisons through genetics and disease associations.
563 Nature. 2023;622:348–58.

564 27. Brown KK, Hann MM, Lakdawala AS, Santos R, Thomas PJ, Todd K. Approaches to
565 target tractability assessment - a practical perspective. Medchemcomm. 2018;9:606–13.

566 28. Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, et al. ChEMBL:
567 towards direct deposition of bioassay data. Nucleic Acids Res. 2019;47:D930–40.

568 29. Hukerikar N, Hingorani AD, Asselbergs FW, Finan C, Schmidt AF. Prioritising genetic
569 findings for drug target identification and validation. Atherosclerosis. 2024;390:117462.

570 30. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
571 resource with deep phenotyping and genomic data. Nature. 2018;562:203–9.

572 31. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization
573 with fine-mapped genetic data: Choosing from large numbers of correlated instrumental
574 variables. Genet Epidemiol. 2017;41:714–25.

575 32. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A
576 framework for the investigation of pleiotropy in two-sample summary data Mendelian
577 randomization. Stat Med. 2017;36:1783–802.

578 33. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
579 Guidelines for performing Mendelian randomization investigations. Wellcome Open Res.
580 2019;4:186.

581 34. Patel A, Ye T, Xue H, Lin Z, Xu S, Woolf B, et al. MendelianRandomization v0.9.0:
582 updates to an R package for performing Mendelian randomization analyses using
583 summarized data. Wellcome Open Res. 2023;8:449.

584 35. Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using
585 summary data. Genet Epidemiol. 2020;44:313–29.

586 36. Burgess S, Thompson SG. Mendelian Randomization: Methods for Using Genetic
587 Variants in Causal Estimation. CRC Press; 2015.

588 37. Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method
589 for Mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11:376.

590 38. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
591 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
592 Epidemiol. 2016;40:304–14.

593 39. Wallace C. Eliciting priors and relaxing the single causal variant assumption in
594 colocalisation analyses. PLoS Genet. 2020;16:e1008720.

595 40. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence
596 from Mendelian randomization and colocalization: Review and comparison of approaches.
597 Am J Hum Genet. 2022;109:767–82.

598 41. Duffy Á, Verbanck M, Dobbyn A, Won H-H, Rein JL, Forrest IS, et al. Tissue-specific
599 genetic features inform prediction of drug side effects in clinical trials. Sci Adv.
600 2020;6:eabb6242.

601 42. Strom NI, Verhulst B, Bacanu S-A, Cheesman R, Purves KL, Gedik H, et al. Genome-
602 wide association study of major anxiety disorders in 122,341 European-ancestry cases
603 identifies 58 loci and highlights GABAergic signaling [Internet]. medRxiv. 2024. Available
604 from: http://medrxiv.org/lookup/doi/10.1101/2024.07.03.24309466

605 43. Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al.
606 Anxious and non-anxious major depressive disorder in the World Health Organization World
607 Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24:210–26.

608 44. Coplan JD, Aaronson CJ, Panthangi V, Kim Y. Treating comorbid anxiety and
609 depression: Psychosocial and pharmacological approaches. World J Psychiatry.
610 2015;5:366–78.

611 45. Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, et al. Major depressive disorder: hypothesis,
612 mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9:30.

613 46. Zhao F, Cheng Z, Piao J, Cui R, Li B. Dopamine Receptors: Is It Possible to Become a
614 Therapeutic Target for Depression? Front Pharmacol. 2022;13:947785.

615 47. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of
616 generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883–92.

617 48. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor
618 properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383–400.

619 49. Egunlusi AO, Joubert J. NMDA receptor antagonists: Emerging insights into molecular
620 mechanisms and clinical applications in neurological disorders. Pharmaceuticals (Basel).
621 2024;17:639.

622 50. Goldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: A mechanistic
623 perspective. Biomolecules. 2022;12:1784.

624 51. Merza Mohammad TA, Merza Mohammad TA, Salman DM, Jaafar HM. Pentoxifylline as
625 a novel add-on therapy for major depressive disorder in adult patients: A randomized,
626 double-blind, placebo-controlled trial. Pharmacopsychiatry. 2024;57:205–14.

627 52. Yasrebi S-O, Momtazmanesh S, Moghaddam HS, Shahmansouri N, Mehrpooya M,
628 Arbabi M, et al. Pentoxifylline for treatment of major depression after percutaneous coronary
629 intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-
630 controlled trial. J Psychosom Res. 2021;150:110635.

631 53. Farajollahi-Moghadam M, Sanjari-Moghaddam H, Ghazizadeh Hasemi M, Sanatian Z,
632 Talaei A, Akhondzadeh S. Efficacy and safety of pentoxifylline combination therapy in major
633 depressive disorder: a randomized, double-blind, placebo-controlled clinical trial: a
634 randomized, double-blind, placebo-controlled clinical trial. Int Clin Psychopharmacol.
635 2021;36:140–6.

636 54. El-Haggar SM, Eissa MA, Mostafa TM, El-Attar KS, Abdallah MS. The
637 phosphodiesterase inhibitor pentoxifylline as a novel adjunct to antidepressants in major
638 depressive disorder patients: A proof-of-concept, randomized, double-blind, placebo-
639 controlled trial. Psychother Psychosom. 2018;87:331–9.

640 55. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting
641 cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290–314.

642 56. Ramzi A, Maya S, Balousha N, Amin M, Powell RC, Shiha MR. Effects of the anti-
643 inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various
644 off-label utilities with meta-analyses. Inflammopharmacology. 2025;33:105–19.

645 57. Brownstein DJ, Salagre E, Köhler C. Blockade of the angio-tensin system improves
646 mental health domain of quality of life: ameta-analysis of randomized clinical trials. Aust N Z
647 J Psychiatry. 2018;52:24–38.

648 58. Vian J, Pereira C, Chavarria V, Köhler C, Stubbs B, Quevedo J, et al. The renin-
649 angiotensin system: a possible new target for depression. BMC Med. 2017;15:144.

650 59. Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Hamad RS, Alexiou A, et al. Role
651 of brain renin-angiotensin system in depression: A new perspective. CNS Neurosci Ther.
652 2024;30:e14525.

653 60. Meng X, Navoly G, Giannakopoulou O, Levey DF, Koller D, Pathak GA, et al. Multi-
654 ancestry genome-wide association study of major depression aids locus discovery, fine
655 mapping, gene prioritization and causal inference. Nat Genet. 2024;56:222–33.

656 61. Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marqués MA, et al. Metformin
657 promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by
658 decreasing circulating branched-chain amino acids. J Neurosci. 2019;39:5935–48.

659 62. Mendonça IP, Paiva IHR de, Duarte-Silva EP, Melo MG de, Silva RS da, Oliveira WH de,
660 et al. Metformin and fluoxetine improve depressive-like behavior in a murine model of
661 Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and
662 neuroplasticity. Int Immunopharmacol. 2022;102:108415.

663 63. Zhang Y, Chan VK-Y, Chan SSM, Chan EWY, Lee CH, Wong IC, et al. Effect of
664 metformin on the risk of depression: A systematic review and meta-regression of
665 observational studies. Asian J Psychiatr. 2024;92:103894.

666 64. Calkin CV, Chengappa KNR, Cairns K, Cookey J, Gannon J, Alda M, et al. Treating
667 insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-
668 resistant bipolar depression (the TRIO-BD study): A randomized, quadruple-masked,
669 placebo-controlled clinical trial: A randomized, quadruple-masked, placebo-controlled clinical
670 trial. J Clin Psychiatry [Internet]. 2022;83. Available from:
671 http://dx.doi.org/10.4088/JCP.21m14022

672 65. Abdallah MS, Mosalam EM, Zidan A-AA, Elattar KS, Zaki SA, Ramadan AN, et al. The
673 antidiabetic metformin as an adjunct to antidepressants in patients with major depressive
674 disorder: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
675 Neurotherapeutics. 2020;17:1897–906.

676 66. Zheng P, Pan C, Zhou C, Liu B, Wang L, Duan S, et al. Contribution of Nischarin/IRAS in
677 CNS development, injury and diseases. J Adv Res. 2023;54:43–57.

678 67. Smith KL, Jessop DS, Finn DP. Modulation of stress by imidazoline binding sites:

679 implications for psychiatric disorders. Stress. 2009;12:97–114.

680 68. Yan S, Xu C, Yang M, Zhang H, Cheng Y, Xue Z, et al. The expression of agmatinase
681 manipulates the affective state of rats subjected to chronic restraint stress.
682 Neuropharmacology. 2023;229:109476.

683 69. Zhu MY, Wang WP, Huang J, Feng YZ, Regunathan S. Bissette Repeated
684 immobilization stress alters rat hippocampal and prefrontal cortical morphology in parallel
685 with endogenous agmatine and arginine decarboxylase levels Neurochem. Neurochem Int.
686 2008;53:346–54.

687 70. Zhu MY, Wang WP, Cai ZW, Regunathan S. Ordway Exogenous agmatine has
688 neuroprotective effects against restraint-induced structural changes in the rat brain Eur. Eur
689 J Neurosci. 2008;27:1320–32.

690 71. Gawali NB, Bulani VD, Gursahani MS, Deshpande PS, Kothavade PS, Juvekar AR.
691 Agmatine attenuates chronic unpredictable mild stress-induced anxiety, depression-like
692 behaviours and cognitive impairment by modulating nitrergic signalling pathway. Brain Res.
693 2017;1663:66–77.

694 72. Kõks S, Luuk H, Nelovkov A, Areda T, Vasar E. A screen for genes induced in the
695 amygdaloid area during cat odor exposure. Genes Brain Behav. 2004;3:80–9.

696 73. Taksande BG, Kotagale NR, Tripathi SJ, Ugale RR, Chopde CT. Antidepressant like
697 effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors
698 by agmatine. Neuropharmacology. 2009;57:415–24.

699 74. Rahangdale S, Fating R, Gajbhiye M, Kapse M, Inamdar N, Kotagale N, et al.
700 Involvement of agmatine in antidepressant-like effect of HMG-CoA reductase inhibitors in
701 mice. Eur J Pharmacol. 2021;892:173739.

702 75. Keller B, García-Sevilla JA. Dysregulation of IRAS/nischarin and other potential I1-
703 imidazoline receptors in major depression postmortem brain: Downregulation of basal
704 contents by antidepressant drug treatments. J Affect Disord. 2017;208:646–52.

705 76. Artegiani B, Lindemann D, Calegari F. Overexpression of cdk4 and cyclinD1 triggers
706 greater expansion of neural stem cells in the adult mouse brain. J Exp Med. 2011;208:937–
707 48.

708 77. Pedraza N, Monserrat MV, Ferrezuelo F, Torres-Rosell J, Colomina N, Miguez-Cabello
709 F, et al. Cyclin D1-Cdk4 regulates neuronal activity through phosphorylation of GABAA
710 receptors. Cell Mol Life Sci. 2023;80:280.

711 78. Li C, Li X, Chen W, Yu S, Chen J, Wang H, et al. The different roles of cyclinD1-CDK4 in
712 STP and mGluR-LTD during the postnatal development in mice hippocampus area CA1.
713 BMC Dev Biol. 2007;7:57.

714 79. de Miranda AS, de Barros JLVM, Teixeira AL. Is neurotrophin-3 (NT-3): a potential
715 therapeutic target for depression and anxiety? Expert Opin Ther Targets. 2020;24:1225–38.

716 80. Desole C, Gallo S, Vitacolonna A, Montarolo F, Bertolotto A, Vivien D, et al. HGF and

717 MET: From brain development to neurological disorders. Front Cell Dev Biol.
718 2021;9:683609.

719 81. Sisi M, Fusaroli M, De Giglio A, Facchinetti F, Ardizzoni A, Raschi E, et al. Psychiatric
720 adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer:
721 Analysis of spontaneous reports submitted to the FDA adverse event reporting system.
722 Target Oncol. 2022;17:43–51.

723 82. Barbieri MA, Russo G, Sorbara EE, Cicala G, Franchina T, Santarpia M, et al.
724 Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic
725 colorectal cancer: an analysis from the FDA Adverse Event Reporting System. Front Oncol.
726 2023;13:1268672.

727 83. Xiao Z, Cao J, Wu S, Zhou T, Li C, Duan J, et al. Spectrum of psychiatric adverse
728 reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the
729 FDA adverse event reporting system. CNS Neurosci Ther. 2024;30:e14862.

730 84. Zhu X, Nedelcovych MT, Thomas AG, Hasegawa Y, Moreno-Megui A, Coomer W, et al.
731 JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents
732 depression-associated behaviors induced by chronic social defeat stress.
733 Neuropsychopharmacology. 2019;44:683–94.

734 85. Bell BJ, Hollinger KR, Deme P, Sakamoto S, Hasegawa Y, Volsky D, et al. Glutamine
735 antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected
736 mice. Brain Behav Immun Health. 2022;23:100478.

737 86. Liy PM, Puzi NNA, Jose S, Vidyadaran S. Nitric oxide modulation in neuroinflammation
738 and the role of mesenchymal stem cells. Exp Biol Med (Maywood). 2021;246:2399–406.

739 87. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J.
740 2012;33:829–37, 837a – 837d.

741 88. Montezuma K, Biojone C, Lisboa SF, Cunha FQ, Guimarães FS, Joca SRL. Inhibition of
742 iNOS induces antidepressant-like effects in mice: pharmacological and genetic evidence.
743 Neuropharmacology. 2012;62:485–91.

744 89. Beheshti F, Hashemzehi M, Hosseini M, Marefati N, Memarpour S. Inducible nitric oxide
745 synthase plays a role in depression- and anxiety-like behaviors chronically induced by
746 lipopolysaccharide in rats: Evidence from inflammation and oxidative stress. Behav Brain
747 Res. 2020;392:112720.

748 90. Coelho AA, Vila-Verde C, Sartim AG, Uliana DL, Braga LA, Guimarães FS, et al.
749 Inducible nitric oxide synthase inhibition in the medial prefrontal cortex attenuates the
750 anxiogenic-like effect of acute restraint stress via CB1 receptors. Front Psychiatry.
751 2022;13:923177.

752 91. Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al.
753 Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open
754 Res. 2021;6:16.

755 92. Yuan Y, Yu L, Bi C, Huang L, Su B, Nie J, et al. A new paradigm for drug discovery in

756 the treatment of complex diseases: drug discovery and optimization. Chin Med. 2025;20:40.

757 93. Jia J, Zhu F, Ma X, Cao Z, Cao ZW, Li Y, et al. Mechanisms of drug combinations:
758 interaction and network perspectives. Nat Rev Drug Discov. 2009;8:111–28.

759 94. Burgess S, Mason AM, Grant AJ, Slob EAW, Gkatzionis A, Zuber V, et al. Using genetic
760 association data to guide drug discovery and development: Review of methods and
761 applications. Am J Hum Genet. 2023;110:195–214.

762 95. Zhao H, Rasheed H, Nøst TH, Cho Y, Liu Y, Bhatta L, et al. Proteome-wide Mendelian
763 randomization in global biobank meta-analysis reveals multi-ancestry drug targets for
764 common diseases. Cell Genom. 2022;2:None.

765 96. Spierling SR, Zorrilla EP. Don’t stress about CRF: assessing the translational failures of
766 CRF1antagonists. Psychopharmacology (Berl). 2017;234:1467–81.

767 97. Miller AH. Advancing an inflammatory subtype of major depression. Am J Psychiatry.
768 2025;appiajp20250289.

769 98. Jiang Y, Peng T, Gaur U, Silva M, Little P, Chen Z, et al. Role of corticotropin-releasing
770 factor in the neuroimmune mechanisms of depression: Examination of current
771 pharmaceutical and herbal therapies. Front Cell Neurosci. 2019;13:290.

**Table 1: Drug targets of positive control compounds for depression and anxiety with significant MR effects and estimated beneficial therapeutic directions on MDD.**

| Target | Tissue (MR effect direction) | Supporting genetic evidence | Estimated therapeutic MOA & drug MOA | Compounds with aligned MOA | Primary indications |
|---|---|---|---|---|---|
| **Monoamine signalling** | | | | | |
| Sodium-dependent serotonin transporter: *SLC6A4* | eQTL blood (+) | Effect direction aligned with beneficial MOA therapeutic effects | Inhibition (-), 28 inhibitors/ antagonists (-) | 21 SSRIs/SNRIs, TCAs, atypical antidepressants | Depression & anxiety |
| Sodium-dependent dopamine transporter: *SLC6A3* | eQTL cortex (+) | Effect direction aligned with beneficial MOA therapeutic effects | Inhibition (-), 10 inhibitors (-) | bupropion | Depression, ADHD (e.g. methylphenidate) |
| Dopamine receptor D2: *DRD2* | eQTLs (+): basal ganglia, hippocampus, spinal cord | Directional consistency, aligned with beneficial MOA therapeutic effects | Inhibition (-), 46 antagonists/ inhibitors (-) | amoxapine, quetiapine prochlorperazine | Depression, anxiety, bipolar disorder, schizophrenia |
| Histamine H1 receptor: *HRH1* | eQTL cortex (+), eQTL blood (+) | Directional consistency, aligned with beneficial MOA therapeutic effects | Inhibition (-), 62 antagonists/ inverse agonists (-) | hydroxyzine, dibenzepin | Depression & anxiety |
| **Glutamatergic signalling** | | | | | |
| NMDA receptor subunits: GRIN1 (+) GRIN2D (+) GRIN2A (-) | pQTL DLPFC (+), eQTL cerebellum (-), pQTL blood (+) | Largely consistent effect across subunits (+) aligned with beneficial MOA therapeutic effects | Inhibition/ activation (-/+), 21 negative allosteric modulator/antagonists/ blocker (-) | esketamine | Treatment-resistant depression |

**Table 1: Drug targets of positive control compounds for depression and anxiety with significant MR effects and estimated beneficial therapeutic directions on MDD.**

| Target | Tissue (MR effect direction) | Supporting genetic evidence | Estimated therapeutic MOA & drug MOA | Compounds with aligned MOA | Primary indications |
|---|---|---|---|---|---|
| **GABA Signalling** | | | | | |
| GABA(A) receptor subunits: *GABRA6* (-) *GABRB2* (-) *GABRG2* (-), *GABRP* (+) | eQTL cerebellum (-/+) | Largely Consistent effect across subunits (-) aligned with beneficial MOA therapeutic effects of anxiolytics | Inhibition/ activation (-/+), 59 positive allosteric modulators/agonist (+) | benzodiazepines, brexanolone, meprobamate | Anxiety, insomnia, anxiety with depressive symptoms, postpartum depression |
| **Calcium Ion Channel Modulators** | | | | | |
| Calcium channel subunits: *CACNG2* (+), *CACNA1G (+)*, *CACNA2D2* (+/-) *CACNA2D4* (-) | eQTLs (+/-): cerebellum, cortex, basal ganglia, hippocampus, blood | Largely consistent effect across subunits (+), robust MR support | Inhibition/ activation (-/+), modulators, blockers (-) | pregabalin | Generalised anxiety disorder, epilepsy, nerve pain |
| **Targets of compounds in clinical trials for depression/anxiety** | | | | | |
| Phosphodiesterases: *PDE6B* (+), *PDE6G* (+), *PDE6H* (+) *PDE3B* (+) *PDE6C* (-) | eQTL blood (+/-) | Largely consistent effect across subtypes (+) aligned with beneficial MOA | Inhibition/ activation (-/+), inhibitors (-) | 9 inhibitors, e.g, pentoxifylline dipyridamole | Cardiovascular (IV), depression (I-II) |
| Corticotropin -releasing factor receptor 1: *CRHR1* | eQTLs: cerebellum (-), cortex (+) | Cortex effect (+) aligned with beneficial MOA, robust MR support | Inhibition/ activation (-/+), 5 antagonists (-) | 5 in clinical trial: e.g. verucerfont, emicerfont, pexacerfont | Depression & anxiety (I-II) |

*Note: A positive (+) MR effect indicates higher expression increases MDD risk, suggesting beneficial compounds would have inhibitory (-) mechanisms of action (MOA) on the target; a negative (-) MR effect indicates lower expression increases risk, suggesting beneficial compounds would have activating (+) mechanisms of action. Consistent MR effect directions across related subunits/subtypes, concordance between tissues, and agreement between genetically estimated therapeutic direction and known clinical efficacy of established drug mechanisms strengthen the validity of our findings. ADHD, attention-deficit/hyperactivity disorder; DLPFC, dorsolateral prefrontal cortex; eQTL, expression quantitative trait loci; MDD, major depressive disorder; MOA, mechanism of action; MR, Mendelian randomisation; pQTL, protein quantitative trait loci.*

772

**Table 2: High-priority brain targets of novel compounds with estimated beneficial therapeutic directions on MDD.**

| Target | Tissue (MR effect) | Supporting genetic evidence | Estimated therapeutic MOA & available drug MOA | Beneficial compounds | Primary indications (depression-related side effects/ clinical trial phase) | Depression relevant mechanisms |
|---|---|---|---|---|---|---|
| Cyclin-dependent kinase 4: *CDK4* | eQTLs: basal ganglia (-), cerebellum (-), hippocampus (-), spinal cord (-), pQTL DLPFC (+) | Directional consistency eQTL brain, external replication pQTL | Mixed: inhibition/ activation (-/+), inhibitor (-) | Crosses BBB: abemaciclib | Breast cancer (fatigue, appetite, psychiatric) | Neuroplasticity, neural activity, neurogenesis |
| Nischarin Imidazoline receptor 1: *NISCH* | eQTLs: cerebellum (+), hippocampus (+), spinal cord (-) | Directional consistency cerebellum & hippocampus | Mixed: inhibition/ activation (-/+), agonist (+) | Crosses BBB: moxonidine, rilmenidine | Hypertension (insomnia, anxiety, depression, psychiatric) | Sympathetic regulation, stress response, target activation has animal model antidepressant-like effects |
| Nitric oxide synthase, inducible: *NOS2* | eQTLs: cortex (+), basal ganglia (+), cerebellum (+) | Directional consistency | Inhibition (-), inhibitor (-) | Clinical trial: tilarginine, KD7040, GW-274150; crosses BBB: BN-4 | Clinical trial: cardiogenic shock (III), migraine (II) | Neuroinflammation, oxidative stress, target inhibition has animal model antidepressant-like effects |
| Glutaminase kidney isoform, mitochondrial: *GLS* | eQTLs: cortex (+), cerebellum (+) | Directional consistency | Inhibition (-), inhibitor (-) | Clinical trial: telaglenastat; crosses BBB: JHU-083 | Clinical trial: cancer (II) | Neuroinflammation, glutamate signalling, target inhibition has animal model antidepressant-like effects |
| Neurotrophic receptor tyrosine kinase 3: *NTRK3* | eQTL cortex (+) | Colocalisation | Inhibition (-), inhibitor (-) | Crosses BBB: entrectinib, larotrectinib | Cancer (anxiety, depression, psychiatric, mood, appetite/weight, fatigue/sleep) | Neuroplasticity, monoamine signalling, HPA axis regulation |
| Angiotensin -converting enzyme: *ACE* | eQTL cortex (+) | MR effect direction aligns with drug MOA & reported mental health benefits | Inhibition (-), inhibitor (-) | Crosses BBB: e.g. captopril, fosinopril, lisinopril | Hypertension (anxiety, depression, mood, appetite/weight, insomnia/sleep) | Neuroinflammation, synaptic plasticity, serotonergic signalling, stress response, ACE inhibitors have antidepressant-like effects in animal models and clinical studies |

**Table 2: High-priority brain targets of novel compounds with estimated beneficial therapeutic directions on MDD.**

| Target | Tissue (MR effect) | Supporting genetic evidence | Estimated therapeutic MOA & available drug MOA | Beneficial compounds | Primary indications (depression-related side effects/ clinical trial phase) | Depression relevant mechanisms |
|---|---|---|---|---|---|---|
| Complex I NADH dehydrogenase subunits: *NDUFA2* (+) *NDUFB6* (+) *NDUFS1* (+) | eQTL cortex (+) | Consistent effect across subunits, robust MR support, reported mental health benefits | Inhibition (-), inhibitor (-) | Crosses BBB: metformin | Type 2 diabetes (appetite) | Mitochondrial function, neuroinflammation, metformin has antidepressant-like effects in animal models and human observational studies |
| Hepatocyte growth factor receptor: *MET* | eQTLs: basal ganglia (+), spinal cord (+) | Directional consistency | Inhibition (-), inhibitor (-) | Crosses BBB: capmatinib, cabozantinib | Cancer (appetite, fatigue, psychiatric) | Neuroplasticity, neurotrophic signalling, neuroinflammation |

*Note: Prioritised targets with novel repurposing opportunities for MDD, i.e. drugs already approved or > Phase I for other indications but not in clinical trial for depression/anxiety as a primary indication. A positive (+) MR effect indicates higher expression increases MDD risk, suggesting beneficial compounds would have inhibitory (-) mechanisms of action (MOA) on the target; a negative (-) MR effect indicates lower expression increases risk, suggesting beneficial compounds would have activating (+) mechanisms of action. Brain targets were prioritised based on: availability of compounds acting in the beneficial direction for at least one tissue, plus clinical relevance (depression-related side effects) or ≥ 1 robust genetic evidence (significant MR effects with directional consistency in multiple brain/nervous system tissues, robust MR support, colocalisation support or pQTL external replication), plus compounds with blood-brain-barrier permeability and plausible depression-relevant biological mechanisms including pre-clinical evidence. BBB, blood-brain barrier; DLPFC, dorsolateral prefrontal cortex; eQTL, expression quantitative trait loci; MDD, major depressive disorder; MOA, mechanism of action; MR, Mendelian randomisation; pQTL, protein quantitative trait loci.*

773 **Figure 1: Novel target identification and prioritisation workflow.** *Flow diagram showing systematic identification of 10 high-priority novel*

774 *drug targets for major depressive disorder from 3,469 druggable genome targets tested in cis-Mendelian randomisation.*


Druggable genome targets tested in MR = 3,469
Significant MR targets = 564
Positive controls = 41
Approved: 19
Clinical trials: 40
Novel targets = 523
Non-robust genetic evidence excluded = 48
PPH3 evidence: 44
Robust MR inconsistent: 3
Blood pQTLs inconsistent: 1
475 targets
1 ≥ Robust genetic evidence = 166
PPH4: 13
Robust MR consistent: 98
pQTL external replication: 22
Brain panel ≥2 directional consistency: 66
Blood panel ≥2 directional consistency: 9
Clinical relevance = 75
Core depression terms: 29
Depression-related terms: 75
216 targets
Predicted beneficial therapeutic direction = 54
Brain & Blood = 4
Brain only = 31
Blood only = 19
High-priority brain targets:
BBB-penetrant compounds + literature support for depression-relevant mechanisms = 10